A: Yes, clinical trials have found that semaglutide (the GLP-1 in the generic medications in Canada) significantly increases a biological marker of bone resorption, indicating bones are being broken down and that there is significantly lower Bone Mineral Density (BMD) at the lumbar spine, total hip, and tibia, which escalates the long-term risk for osteoporosis and fractures
High fever affects multiple body systems: Increases fluid loss through sweating Accelerates metabolism and energy expenditure Can affect how medications are processed May indicate bacterial infection requiring antibiotics Gastrointestinal Illness Stomach bugs, food poisoning, or severe gastrointestinal flu present special challenges on GLP-1 therapy
Preclinical CagriSema data suggests it may preserve energy expenditure by maintaining mitochondrial function in skeletal muscle, which could theoretically support better muscle preservation over time
Online platforms typically provide detailed product information, including dosage guidelines, storage requirements, and administration instructions
In terms of metabolic outcomes, semaglutide consistently outperforms exenatide in both glycemic control and weight reduction across comparison studies
Because retatrutide is not licensed in the UK, it should not be bought online or used outside an authorised clinical trial